Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Pembrolizumab in HLA-A2+ Patients With Metastatic Triple Negative Breast Cancer (TNBC)

NCT03362060 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT03362060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03362060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Pembrolizumab in HLA-A2+ Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 12, 2017
Completion date
December 30, 2027
Enrollment
20 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, triple negative breast cancer